Published in J Biol Regul Homeost Agents on June 08, 2000
Hiv-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. J Pediatr (2006) 1.61
Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol (2003) 1.41
Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses (2010) 1.05
Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PLoS One (2013) 0.96
Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus. J Virol (2004) 0.91
Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals. J Virol (2004) 0.87
Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. J Virol (2008) 0.85
Are anti-HIV IgAs good guys or bad guys? Retrovirology (2014) 0.83
HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis. J Virol (2016) 0.75
Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy. PLoS One (2017) 0.75
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med (1997) 4.21
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 3.75
Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev (1992) 3.30
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med (1997) 3.22
The checkpoint protein Ddc2, functionally related to S. pombe Rad26, interacts with Mec1 and is regulated by Mec1-dependent phosphorylation in budding yeast. Genes Dev (2000) 2.82
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev (1996) 2.77
Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med (1999) 2.54
Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst (1997) 2.45
The 1997 Nationwide Tuberculosis Prevalence Survey in the Philippines. Int J Tuberc Lung Dis (1999) 2.30
On the process of cellular division in Escherichia coli. IV. Altered protein composition and turnover of the membranes of thermosensitive mutants defective in chromosomal replication. J Mol Biol (1971) 2.19
An immunoendocrinological hypothesis of HIV infection. Lancet (1994) 2.19
On the process of cellular division in Escherichia coli. Membrane prtein alterations associated with mutations affecting the initiation of DNA synthesis. J Mol Biol (1970) 2.15
ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest (1995) 2.04
The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res (1996) 2.04
T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood (2000) 1.94
Early T-helper cell defects in HIV infection. AIDS (1991) 1.93
Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol (1996) 1.93
Immune activation in africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS (2000) 1.91
HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS (1999) 1.89
Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol (1998) 1.89
Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis (1999) 1.88
Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. AIDS (1998) 1.86
Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol (1993) 1.84
Hawking radiation from ultrashort laser pulse filaments. Phys Rev Lett (2010) 1.80
Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J Clin Invest (1989) 1.77
Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today (1996) 1.75
Tuberculosis in the urban poor settlements in the Philippines. Int J Tuberc Lung Dis (2000) 1.71
Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol (2000) 1.69
In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis (1995) 1.69
Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS (2000) 1.66
Falls in older Mexican-American women. J Am Geriatr Soc (1999) 1.66
Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer (2003) 1.65
AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy (2008) 1.59
Alloimmunization as an AIDS vaccine? Science (1993) 1.58
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1997) 1.54
Mammalian LIN-7 PDZ proteins associate with beta-catenin at the cell-cell junctions of epithelia and neurons. EMBO J (2000) 1.53
Characterization of mec1 kinase-deficient mutants and of new hypomorphic mec1 alleles impairing subsets of the DNA damage response pathway. Mol Cell Biol (2001) 1.53
p95-APP1 links membrane transport to Rac-mediated reorganization of actin. Nat Cell Biol (2000) 1.53
Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins? AIDS Res Hum Retroviruses (1992) 1.51
Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy. Lancet (1998) 1.50
HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol (2009) 1.49
The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci (2005) 1.48
Evidence for the expression of HLAA-C class I mRNA and protein by human first trimester trophoblast. J Immunol (1996) 1.46
Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J Clin Invest (1991) 1.44
In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J Infect Dis (1996) 1.41
Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. J Pediatr (1999) 1.41
Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res (1996) 1.39
Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS (1996) 1.39
A strategy for prophylactic vaccination against HIV. Science (1993) 1.38
Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res (1991) 1.38
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS (1999) 1.36
Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J Infect Dis (1996) 1.36
CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Clin Exp Immunol (1996) 1.35
Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med (1999) 1.32
CXCR4 is a functional coreceptor for infection of human macrophages by CXCR4-dependent primary HIV-1 isolates. J Immunol (1998) 1.32
Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS (1997) 1.32
Mechanism of residence of cytochrome b(5), a tail-anchored protein, in the endoplasmic reticulum. J Cell Biol (2000) 1.31
Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett (2001) 1.31
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol (2011) 1.30
Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med (1997) 1.28
CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J Immunol (2000) 1.28
An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1990) 1.28
Colicin resistance associated with resistance factors in Escherichia coli. Genet Res (1966) 1.26
Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol (1993) 1.25
PDZ-mediated interactions retain the epithelial GABA transporter on the basolateral surface of polarized epithelial cells. EMBO J (1999) 1.25
C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells. J Exp Med (1997) 1.24
Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med (1996) 1.23
Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood (1996) 1.23
T-helper cell responses to HIV envelope peptides in cord blood: protection against intrapartum and breast-feeding transmission. AIDS (2001) 1.23
The specific subcellular localization of two isoforms of cytochrome b5 suggests novel targeting pathways. J Biol Chem (1993) 1.22
Synchronous germination and outgrowth of fractionated Bacillus subtilis spores: tool for the analysis of differentiation and division of bacterial cells. J Bacteriol (1975) 1.21
Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost (2009) 1.19
The GLT-1 and GLAST glutamate transporters are expressed on morphologically distinct astrocytes and regulated by neuronal activity in primary hippocampal cocultures. J Neurochem (2000) 1.19
Replication of hepatitis C virus in B lymphocytes (CD19+) Blood (1999) 1.18
Effect of some R factors on the sensitivity of rough Enterobacteriaceae to human serum. Infect Immun (1977) 1.18
Syntaxin 1A is delivered to the apical and basolateral domains of epithelial cells: the role of munc-18 proteins. J Cell Sci (2001) 1.17
Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS (2001) 1.16
Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori (1982) 1.16